Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study
AtaCor Medical, Inc. · NCT07324031
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 280
- US sites recruiting
- 12
- Study start
- July 2, 2026
- Record last updated
- October 9, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The ALARION EV Study is a prospective, multi-center, single-arm, non-randomized study without concurrent or historical controls. The purpose of this pivotal study is to generate evidence of safety and effectiveness to apply for regulatory approvals for commercialization of the Parasternal EV-ICD System.
The objective of the study is to demonstrate safety and effectiveness of the Parasternal EV-ICD System through 6-months.
Being studied: Atala™ lead and EV-ICD Pulse Generator
Conditions: Ventricular Arrythmia; Ventricular Fibrillation; Ventricular Tachycardia
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- At least 18 years old
- Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines or ESC guidelines
Exclusion Criteria
- Patients who cannot read or write
- Expected survival \< 1 year
- Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period
- Participation in any concurrent clinical study without prior approval from the Sponsor
- Inability or unwillingness to provide informed consent to participate in the study
- Any known circumstances which may prevent the completion of protocol testing and data collection through the 6-month follow-up visit
- Circumstances that may prevent data collection or completion of specified follow-up visits
- Allergies to any device materials listed in the Instructions for Use (IFU)
- Contraindication for temporary suspension of oral/systemic anticoagulation
- Known history of lung disease with FEV1 \< 1.0 Liter
Device Related
- Implanted with or planned implantation of any device which delivers current in the body that may interfere with therapy delivery, including, but not limited to a pacemaker, LVAD or neurostimulator
- Implanted with a subcutaneous ICD lead, subcutaneous coils/arrays, epicardial patches or epicardial pace/sense leads
- Any known need for MRI prior to approval of MRI conditional labeling
Anatomy Related
- Known structural abnormalities of the heart that may increase risk of the Parasternal EV-ICD System procedure
- Known obstructed or restricted pathway into the mediastinum for the Atala™ lead
- Prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium, including sternotomy of any type
- Known significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis)
- History of thoracic radiation therapy or other medical treatments/conditions which may complicate the Parasternal EV-ICD System implant procedure
- Known adhesions in the thorax or history of medical treatments, surgeries or conditions that increase the potential for adhesions in the thorax
- Surgically corrected congenital heart disease (not including catheter-based procedures)
Cardiac Related
- Indication for permanent bradycardia pacing or cardiac resynchronization therapy
- Decompensated heart failure
- Currently on inotropic therapy
- Known history of pericardial disease, pericarditis or mediastinitis
- Risk factors associated with defibrillation testing:
- Severe aortic stenosis
- Current Intracardiac LA or LV thrombus
- Severe proximal three-vessel or left main coronary artery disease without revascularization
- Hemodynamic instability
- Unstable angina
- Recent stroke or transient ischemic attack (within the last 3 months)
- Known inadequate external defibrillation
- LVEF \< 20% (most recent assessment; must be within 180 days of consent)
- LVEDD >70 mm (most recent assessment; must be within 180 days of consent)
Recruiting US locations
St. Bernards Heart and Vascular
Jonesboro, AR 72401
Site contact: Devi Nair, MD
Mount Sinai Medical Center of Florida
Miami Beach, FL 33140
Site contact: Raul Weiss, MD
Emory University
Atlanta, GA 30308
Site contact: Mikhael El Chami, MD
Endeavor Health
Glenview, IL 60026
Site contact: Mark Metzl, MD
Baptist Health
Lexington, KY 40503
Site contact: Johan Aasbo, DO
John Hopkins Medical
Baltimore, MD 21287
Site contact: Edward Powers, MD
Mayo Clinic
Rochester, MN 55902
Site contact: Paul Friedman, MD
Northwell Health
Manhasset, NY 11030
Site contact: Laurence Epstein, MD
Advocate/Atrium Health - Sanger Heart and Vascular
Charlotte, NC 28204
Site contact: Satish Misra, MD
Advocate/Atrium Health - Wake Forest Baptist
Winston-Salem, NC 27157
Site contact: Satish Misra, MD
The Carl & Edyth Lindner Center for Research and Education at The Christ Hospital
Cincinnati, OH 45219
Site contact: Daniel Pelchovitz, MD
Texas Cardiac Arrhythmia Research
Austin, TX 78705
Site contact: Amin Al-Ahmad, MD
Study contacts (from the official record)
- Sarah Hase, BS, CCRA · +1 949-545-9820 · sarah@atacor.com